Fig. 7
Efficacy of CXCR3 blockade on peritoneal progression of p53(-/-) ID8 EOC and the survival of C57BL6 mice. Mice (Control group, n = 5; CXCR3 mAb group, n = 4) were inoculated ip with ID8 cells and treated ip with vehicle or CXCR3 mAb for 5 weeks. The ACs of mice were measured to determine the percentage increase in AC. The body weight of mice was measured to monitor treatment toxicity (A). The Kaplan-Meier survival curve and median survival time of mice were determined using a 50% increase in AC as the endpoint (B). Mice (n = 5) were inoculated ip with ID8 cells and treated ip with vehicle, AMG487, bevacizumab (Bev), or both in combination for 5 weeks. Bev group, n = 4. The ACs of mice were measured to determine the percentage increase in AC. The body weight of mice was measured to monitor treatment toxicities. Data are means ± SD.*, p < 0.05; **, p < 0.01 (C). The Kaplan-Meier survival curve and median survival time of mice were determined using a 50% increase in AC as the endpoint. p values are shown (D). Mice (n = 5 and n = 3 from two experiments) inoculated ip with ID8 cells were treated with vehicle or AMG487 for 5 weeks. When mice reached the survival endpoint, tumor ascites was obtained and CD3+ T cells were isolated, stained, and analyzed by a flow cytometer to determine the percentages of activated CD8+ T cells and FOXP3+CD4+ Tregs in total CD3+ T cells. Each dot represents the value of an individual mouse. Means and SD of all mice in each treatment group, and p values are shown (E).
